Research and Markets: Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market" report to their offering.

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy and highlights the key opportunities and challenges presented by both business models

On 26th January 2009, Pfizer announced plans to acquire Wyeth for $68 billion. Pfizer's CEO, Jeffrey B Kindler, insisted the deal would be different from the company's earlier mega-deals involving the acquisitions of Pharmacia (2002) and Warner-Lambert (2000) - the acquisition of Wyeth would provide a broad and diversified portfolio, rather than been focused on a single product or cost-cutting. Pfizer's strategy of growing its portfolio through a mega M&A deals follows the 2008 acquisitions of Millennium by Takeda and ImClone by Eli Lilly.

Some key findings from the report

  • Significant industry consolidation will lead to a fundamental shift in the market dynamics across all major product categories.
  • Since the beginning of 2006 a total of seven deals have been agreed with total transaction fees in excess of US$10 billion.
  • It appears likely that the mega-M&A wave started by the 3 deals in Q109 is not yet finished.
  • A handful of major players will follow in the footsteps of Pfizer and enter into major M&A transactions involving a significant step change in market shares and industry consolidation.

Companies Mentioned:

  • Abbott Labs
  • Amgen
  • AstraZeneca
  • Bayer/Schering AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo/Ranbaxy
  • Eisai/MGI Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Merck KGaA/Serono
  • Merck/Schering-Plough
  • Novartis
  • Novo Nordisk
  • Nycomed/Altana Pharma
  • Pfizer
  • Pfizer/Wyeth
  • Roche
  • Roche/Genentech
  • Sanofi-Aventis
  • Schering-Plough
  • Schering-Plough/Organon
  • Takeda
  • Takeda/Millennium
  • Teva
  • Teva/Barr Labs
  • UCB/Schwarz Pharma
  • Wyeth

For more information visit

Source: Spectra Intelligence


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical